Sarepta Therapeutics Inc (SRPT)

NASDAQ
66.56
-0.23(-0.34%)
  • Volume:
    291,730
  • Bid/Ask:
    66.57/66.61
  • Day's Range:
    65.59 - 67.40

SRPT Overview

Prev. Close
66.79
Day's Range
65.59-67.4
Revenue
573.35M
Open
66.31
52 wk Range
65.36-181.6
EPS
-8.94
Volume
291,730
Market Cap
5.33B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,585,552
P/E Ratio
-
Beta
1.38
1-Year Change
-57.9%
Shares Outstanding
79,774,575
Next Earnings Date
Oct 27, 2021
What is your sentiment on Sarepta Therapeutics Inc?
or
Vote to see community's results!

Sarepta Therapeutics Inc News

Sarepta Therapeutics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralBuySellStrong SellSell
Technical IndicatorsStrong BuyStrong BuyStrong SellStrong SellStrong Sell
SummaryBuyStrong BuyStrong SellStrong SellStrong Sell

Sarepta Therapeutics Inc Company Profile

Sarepta Therapeutics Inc Company Profile

Sector
Services
Employees
866

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children’s Hospital; Lysogene; Duke University; Genethon; and StrideBio. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Read More
  • Huge Discount BUY BUY BUY!!!
    1
    • Target is 82$
      1
      • this company is trash
        0
        • On the 19th you said it will hit 100s, make up your mind
          0
        • it will but looks like it will take 3 months. But I added 100 lots more.
          0
        • I was hopeful it would bounce from the over reaction, bought at $91 after the dip...playing the long game now, but painful right now
          0
      • Going big.
        0
        • market is ********up right now. just wait couple months and it will hit 100s
          0
          • Sell on the news
            0
            • link?
              0
          • 115 !!!
            0
            • Buy. Target 115-120$
              0
              • arkg buy yesterday
                0
                • The Food and Drug Administration is scheduled to rule on Sarepta Therapeutics Inc's (NASDAQ: SRPT) new drug application for casimersen, a treatment for patients with Duchenne muscular dystrophy who have certain genetic mutations. The PDUFA goal date is Thursday, Feb. 25.
                  0
                  • CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2020 financial results after the Nasdaq Global Market closes on Monday, March 1, 2021. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full year 2020 financial results and to provide a corporate update.
                    0
                    • Qwerty
                      0
                      • Letsgoo
                        0
                        • CAMBRIDGE, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on January 29, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 26 individuals hired by Sarepta in January 2021. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received, in the aggregate, options to purchase 20,565 shares of Sarepta's common stock, and in the aggregate, 7,760 restricted stock units (“RSUs”). The options have an exercise price of $89.40 per share, which is equal to the closing price of Sarepta's common stock on January 29, 2021 (the “Grant Date”). One-fourth of the shares underlying each employee’s option will vest on the one-year anniversary of the Grant Date and thereafter 1/48th of the shares underlyi
                          0
                          • about to take off... all aboard
                            0
                            • 2.7 million pump
                              0
                          • sarepta is going back to the sky
                            2
                            • pre-market is good, planning to rich TP on 208 this week
                              1
                              • should be resistance at 208
                                1
                              • Alex Bugaj can you explain resistance at 208. Why would you say that?
                                0
                              • In Singh on 1h chart draw support & resistance levels starting from 08.01.21. It'll show what tomorrow after the market open need to TP if you are going short (it'll be about ± $104.5 per share)
                                0
                            • this is will go back to his hight. with earning coming, it should break 100 easily soon
                              0
                              • Let's pump to $120
                                1
                                • I smell money
                                  0
                                  • Can somebody explain this fall please?
                                    0
                                    • will definetly get over 120$ very soon
                                      0
                                      • You definitely have zero clue about that
                                        0
                                    • I change my mind. I'm in
                                      0
                                      • 50
                                        5
                                        • Get to 100!!
                                          0
                                          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.